Jornal Brasileiro de Pneumologia · 2015 · 24 citations · 6 references
PharmacyPharmacoeconomicsCost-effectiveness AnalysisDiagnostic MicrobiologyMolecular DiagnosticsCost Data CollectionDiagnostic Test UtilizationHealthcare Cost AnalysisMycobacterial DiagnosticsTuberculosis DiagnosisTuberculosis Diagnostic TestingDiagnostic Cost AnalysisDiagnostic Test CostsNucleic Acid AmplificationNucleic Acid Amplification DiagnosticsPulmonary Tuberculosis DiagnosisSputum Smear MicroscopyTuberculosis DiagnosticsTuberculosis Molecular Testing
We estimated the costs of a molecular test for Mycobacterium tuberculosis and resistance to rifampin (Xpert MTB/RIF) and of smear microscopy, within the Brazilian Sistema Único de Saúde (SUS, Unified Health Care System). In SUS laboratories in the cities of Rio de Janeiro and Manaus, we performed activity-based costing and micro-costing. The mean unit costs for Xpert MTB/RIF and smear microscopy were R$35.57 and R$14.16, respectively. The major cost drivers for Xpert MTB/RIF and smear microscopy were consumables/reagents and staff, respectively. These results might facilitate future cost-effectiveness studies and inform the decision-making process regarding the expansion of Xpert MTB/RIF use in Brazil.
6
The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa
Gesine Meyer‐Rath, Kathryn Schnippel, Lawrence Long et al. · PLoS ONE · 2012 · 161 citations · Full text
Public Health, Infectious Disease Control, Pharmacoeconomics +17
Betina Durovni, Valéria Saraceni, Susan van den Hof et al. · PLoS Medicine · 2014 · 145 citations · Full text
Public Health, Clinical Sciences, Infectious Disease Control +16
Maunank Shah, Violet Chihota, Gerrit Coetzee et al. · BMC Infectious Diseases · 2013 · 66 citations · Full text